Parallel Advisors, LLC Enanta Pharmaceuticals Inc Transaction History

Parallel Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 20, 2024	BUY	$20.68 - $39.85 $268 - $518	13 New	13 $0
Q2 2023 Aug 04, 2023	BUY	$20.68 - $39.85 $268 - $518	13 New	13 $0
Q2 2022 Aug 01, 2022	SELL	$38.13 - $76.93 $6,253 - $12,616	-164 Closed	0 $0
Q1 2022 Apr 28, 2022	SELL	$56.06 - $74.11 $32,907 - $43,502	-587 Reduced 78.16%	164 $11,000
Q4 2021 Jan 20, 2022	SELL	$60.19 - $97.37 $842 - $1,363	-14 Reduced 1.83%	751 $56,000
Q3 2021 Nov 02, 2021	BUY	$41.02 - $58.65 $27,360 - $39,119	667 Added 680.61%	765 $43,000
Q2 2021 Aug 06, 2021	BUY	$43.76 - $53.11 $2,231 - $2,708	51 Added 108.51%	98 $4,000
Q4 2020 Feb 02, 2021	SELL	$41.16 - $47.47 $2,181 - $2,515	-53 Reduced 53.0%	47 $2,000
Q3 2020 Oct 27, 2020	BUY	$43.36 - $53.53 $2,818 - $3,479	65 Added 185.71%	100 $5,000
Q2 2020 Jul 16, 2020	BUY	$46.37 - $57.58 $1,622 - $2,015	35 New	35 $1,000
Q2 2018 Jul 30, 2018	SELL	$81.85 - $120.51 $28,483 - $41,937	-348 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$57.91 - $92.15 $20,152 - $32,068	348 New	348 $28,000

108

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $109M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.